G17DT + irinotecan

G17DT + irinotecan is a combination therapy investigated for the treatment of advanced gastrointestinal cancers, particularly in patients refractory to standard chemotherapy. G17DT is a novel immunogen that induces antibodies against gastrin 17, a growth factor implicated in the proliferation of certain gastrointestinal tumors. By neutralizing gastrin 17, G17DT aims to inhibit tumor growth. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication in cancer cells, leading to cell death. The combination has been studied in phase II trials for advanced colorectal cancer and other gastrointestinal malignancies, showing an acceptable safety profile and potential survival benefit correlated with anti-Gastrin immune response[2][3][6].

Brand names

Camptosar (for irinotecan)Onivyde (for irinotecan)Campto (for irinotecan)

Other names

Gastrin 17 immunogenGastrin17 immunogenGastrin-17 immunogenGastrin 17 vaccineGastrin17 vaccineGastrin-17 vaccineGastrin 17C Diphtheria Toxoid ImmunogenGastrin17C Diphtheria Toxoid ImmunogenGastrin-17C Diphtheria Toxoid Immunogen